Advertisement

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma

Abstract

ABSTRACT Objective

Homologous recombination (HR) is frequently impaired in sporadic high-grade serous ovarian carcinoma (sHGSOC) due to deficiencies in BRCA1/2 genes, a situation associated with hypersensitivity to platinum compounds. Alterations in other genes can also cause HR deficiency. Preclinical data show that RAP80 is an HR–pathway-related gene that influences BRCA1 activity. RAP80 has been reported to affect outcome in some solid neoplasms. This study investigates the role of RAP80 in sHGSOC survival.

Methods

mRNA expression of RAP80 was analyzed in tumor samples from 35 patients who postoperatively received standard platinum-based chemotherapy. The effects of RAP80 expression on progression-free survival (PFS) and overall survival (OS) were examined by means of Cox regressions. The clinical variables known to have prognostic value (FIGO stage, residual disease at surgery, and debulking surgery) were included as covariates in the analysis. BRCA1 was analyzed given the moderate correlations with RAP80.

Results

Median follow-up, PFS and OS were 61.3, 20.2 and 62.8 months, respectively. Low RAP80 expression levels were associated with shorter PFS (HR = 1.449, p = 0.007) and OS (HR = 1.331, p = 0.047).

Conclusions

This is the first study to show a potential prognostic role of RAP80 expression in patients with HGSOC. The results suggest that HR deficiency due to low RAP80 expression is not associated with hypersensitivity to platinum compounds in sHGSOC.

Int J Biol Markers 2017; 32(1): e90 - e95

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/jbm.5000223

Authors

Margarita Romeo, Niki Karachaliou, Imane Chaid, Cristina Queralt, Itziar De Aguirre, María del Carmen Gómez, María Sanchez-Ronco, Joaquim Radua, José Luís Ramírez, Rafael Rosell

Article History

Disclosures

Financial support: The work in Dr Rosell’s laboratory is partially supported by grants from Fundació La Caixa and the Redes Temáticas de Investigación en Cáncer (RTICC; grant RD12/0036/0072). Neither of these funding organizations had any input in the design of the study, the collection of data, or the decision to publish.
Conflict of interest: The authors declare that there are no conflicts of interests.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Medical Oncology Department, Catalan Institute of Oncology, Badalona - Spain
  •  Department of Medicine, Autonomous University of Barcelona, Barcelona - Spain
  •  Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona - Spain
  •  Translational Research Laboratory, Institut d’Investigació Germans Trias i Pujol, Badalona - Spain
  •  Pathology Department, Hospital Germans Trias i Pujol, Badalona - Spain
  •  Faculty of Medicine, Universidad Alcala de Henares, Madrid - Spain
  •  FIDMAG Germanes Hospitalàries - CIBERSAM, Sant Boi de Llobregat - Spain
  •  Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona - Spain

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

This article has supplementary materials available to download.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.